MIST Retreatment Rates: What the 2026 Data Shows

Retreatment rate has become a central metric for evaluating BPH MIST durability. As five-year data accumulates across device categories, clear patterns are emerging. This article reviews the available evidence and explores the procedure-specific factors that influence long-term durability.

Why retreatment rates differ

The mechanism of action strongly predicts long-term durability. Procedures that remove or ablate tissue (TURP, laser) show the lowest retreatment rates but at the cost of higher morbidity. MIST procedures trade some durability for lower complication profiles — but the durability gap varies significantly between MIST approaches.

(Table) Procedure · 12-month · 24-month · 36-month · 5-year

• Nexusuro (TUCBDP) · 0.9% · 2.6% · 4.5% · ~5%*
• UroLift · 2.5-3.0% · 5.0-6.5% · 8.0-10.5% · ~13%*
• Rezūm · 1.5-2.0% · 3.5-5.0% · 6.5-8.0% · ~8%*

*5-year data for MIST remains limited. Published figures are projections from Kaplan-Meier curves of ongoing follow-up cohorts. TUCBDP data from Gen 1 registration study, N=186 at 36 months.

The anatomy of retreatment

UroLift retreatment is primarily driven by implant-related issues: encrustation, migration, or symptom recurrence in untreated lateral lobes. Rezūm retreatment often relates to incomplete initial ablation — under-treated tissue continues to obstruct. TUCBDP mechanical dilation, by creating a full-column radial expansion, addresses the prostatic urethra uniformly, which may explain the lower retreatment trajectory.

What this means for clinical decision-making

For younger patients (under 65), retreatment probability over their remaining lifespan is a material consideration. A 45-year-old with a projected 40-year lifespan faces meaningfully different odds of retreatment depending on the initial procedure chosen. MIST-first strategies preserve TURP as a future option — but choosing the right MIST matters.